09.13.12
NattoPharma, Oslo, Norway, international supplier of MenaQ7 and leader in the health effects of vitamin K-2, has announced it will expand its portfolio as a result of extended research and development, which led the ingredient innovator to develop new natural crystallized MenaQ7 products.
“The most significant technological breakthrough in the new generation of MenaQ7 is a proprietary multi-step process of purification, condensation and crystallization of fermentation-derived K2. This process leads to an end product that has more than 95% pure natural menaquinone-7, a much more desirable outcome for the safety and efficacy of the end product,” explains Dr. Vladimir Badmaev, head of Research and Development of NattoPharma.
The new pure MenaQ7 crystals can be used directly in food, food supplements, premixes and multivitamins without the customary excipients— resulting in much desired space and weight savings in finished vitamin K2-containing products.
NattoPharma will be hosting a suite at Supply Side West to discuss its latest MenaQ7 crystal technology and results of its three-year study. For further information, contact Frode Bohan, chairman of the board of NattoPharma directly at Frode@nattopharma.com or visit www.menaq7.com
“The most significant technological breakthrough in the new generation of MenaQ7 is a proprietary multi-step process of purification, condensation and crystallization of fermentation-derived K2. This process leads to an end product that has more than 95% pure natural menaquinone-7, a much more desirable outcome for the safety and efficacy of the end product,” explains Dr. Vladimir Badmaev, head of Research and Development of NattoPharma.
The new pure MenaQ7 crystals can be used directly in food, food supplements, premixes and multivitamins without the customary excipients— resulting in much desired space and weight savings in finished vitamin K2-containing products.
NattoPharma will be hosting a suite at Supply Side West to discuss its latest MenaQ7 crystal technology and results of its three-year study. For further information, contact Frode Bohan, chairman of the board of NattoPharma directly at Frode@nattopharma.com or visit www.menaq7.com